OBJECTIVES: Forty percent of women with ovarian carcinoma have circulating free neoplastic DNA identified in plasma. Angiogenesis is critical in neoplastic growth and metastasis. We sought to determine whether circulating neoplastic DNA results from alterations in the balance of angiogenesis activators and inhibitors. METHODS: Sixty patients with invasive ovarian carcinomas with somatic TP53 mutations that had been characterized for circulating neoplastic DNA had carcinoma analyzed for microvessel density using immunohistochemistry with CD31 and for the expression of VEGF, ANGPT1, ANGPT2, PTGS2, PLAU, THBS1, CSF1, PIK3CA, HIF1A, IL8, MMP2, and MMP9 message by real-time quantitative polymerase chain reaction. The expression of each gene was ...
Objective: The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to ...
Background: Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma a...
BACKGROUND: Germline mutations in BRCA1 and BRCA2 are responsible for 5%-10% of epithelial ovarian c...
Objective: Circulating tumor DNA (ctDNA) offers a minimally-invasive alternative to study genomic ch...
Mutations of the p53 tumor suppressor gene are associated with large differences (>7 vessels/HPF) in...
International audience5548 Background: Ovarian cancer is the leading cause of death by gynecological...
Objectives: Underlying mechanisms regulating angiogenesis in ovarian cancer have not been completely...
Purpose: High-grade serous epithelial ovarian cancer (HGS-EOC) is defined by high levels of somatic ...
Background: We investigated whether mutations in plasma circulating tumor DNA (ctDNA) can provide pr...
International audienceIntroduction The poor prognosis of ovarian carcinoma (OvC) is due to the advan...
AbstractRetrospective studies have demonstrated that nearly 50% of patients with ovarian cancer with...
Background: Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma a...
Summary. Breast cancer is the most common malignant tumor in women around the world. It is a disease...
SummaryBackgroundHuman ovarian carcinoma is a silent killer. Most patients with human ovarian carcin...
© 2011 Dr. Manasa RamakrishnaOvarian cancer is a heterogeneous, genomically unstable and highly leth...
Objective: The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to ...
Background: Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma a...
BACKGROUND: Germline mutations in BRCA1 and BRCA2 are responsible for 5%-10% of epithelial ovarian c...
Objective: Circulating tumor DNA (ctDNA) offers a minimally-invasive alternative to study genomic ch...
Mutations of the p53 tumor suppressor gene are associated with large differences (>7 vessels/HPF) in...
International audience5548 Background: Ovarian cancer is the leading cause of death by gynecological...
Objectives: Underlying mechanisms regulating angiogenesis in ovarian cancer have not been completely...
Purpose: High-grade serous epithelial ovarian cancer (HGS-EOC) is defined by high levels of somatic ...
Background: We investigated whether mutations in plasma circulating tumor DNA (ctDNA) can provide pr...
International audienceIntroduction The poor prognosis of ovarian carcinoma (OvC) is due to the advan...
AbstractRetrospective studies have demonstrated that nearly 50% of patients with ovarian cancer with...
Background: Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma a...
Summary. Breast cancer is the most common malignant tumor in women around the world. It is a disease...
SummaryBackgroundHuman ovarian carcinoma is a silent killer. Most patients with human ovarian carcin...
© 2011 Dr. Manasa RamakrishnaOvarian cancer is a heterogeneous, genomically unstable and highly leth...
Objective: The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to ...
Background: Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma a...
BACKGROUND: Germline mutations in BRCA1 and BRCA2 are responsible for 5%-10% of epithelial ovarian c...